A Phase I, Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants

The primary objective of this study is to evaluate the safety and pharmacokinetics of GRT6019 in healthy male participants. Assessment of these parameters is essential for characterizing the initial tolerability profile and the metabolic disposition of the investigational product.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers. The cohort is composed of males within the age range of 19 to 45 years. No specific medical conditions are applicable for this Phase I study.

This Phase I clinical trial is designed to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants. The study follows a controlled research methodology. The sequence of study procedures begins with a screening visit to assess eligibility. Subsequent follow-up visits are conducted to monitor clinical data, concluding with an end-of-study visit. The total duration of participant involvement is determined by the specific protocol requirements. Participation may be discontinued if predetermined clinical criteria for early termination are met.

Information regarding the specific efficacy assessment parameters, measurement methods, or clinical instruments is not available in the provided source material.